Richard Buchta
Director/Board Member bei BERONI GROUP LIMITED
Profil
Richard Buchta is currently a Director at Opal Biosciences Ltd., an Independent Non-Executive Director at Beroni Group Ltd., and a Director at Formulytica Pty Ltd.
He previously worked as a Senior Vice President-Research & Development at Vyome Therapeutics, Inc. Buchta received his undergraduate degree from Monash University, an MBA from Deakin University, and doctorates from the Weizmann Institute of Science and the University of Trieste.
Aktive Positionen von Richard Buchta
| Unternehmen | Position | Beginn |
|---|---|---|
| BERONI GROUP LIMITED | Director/Board Member | 01.07.2020 |
Formulytica Pty Ltd.
 Formulytica Pty Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Opal Biosciences Ltd., Formulytica Pty Ltd. is a specialty research organization that provides regulatory solutions, training in formulation and analytical techniques, and troubleshooting formulation and analytical methods. The private company is based in Mulgrave, Australia. The Australian company specializes in contract formulation development services, analytical method development and validation, new product development, and the analytical science of semi-solid formulations. Formulytica was acquired by Opal Biosciences Ltd. on May 05, 2021. | Director/Board Member | - |
Opal Biosciences Ltd.
 Opal Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Opal Biosciences Ltd. develops antimicrobial and anti-infective products. The company was founded in and is headquartered in South Melbourne, Australia. | Director/Board Member | 05.05.2021 |
Ehemalige bekannte Positionen von Richard Buchta
| Unternehmen | Position | Ende |
|---|---|---|
Vyome Therapeutics, Inc.
 Vyome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Vyome Therapeutics, Inc. develops research-based dermatology pharmaceutical solutions. It also develops drugs for antibiotics-resistant acne and other pathogens through a pipeline of antibiotics that retard resistance development. The company was founded by Rajesh Sudhir Gokhale, Rajeev Mantri, Venkateswarlu Nelabhotla, and Shiladitya Sengupta in August 2010 and is headquartered in Princeton, NJ. | Chief Tech/Sci/R&D Officer | - |
Ausbildung von Richard Buchta
| Monash University | Undergraduate Degree |
| Deakin University | Masters Business Admin |
| Weizmann Institute of Science | Doctorate Degree |
| University of Trieste | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| BERONI GROUP LIMITED | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Vyome Therapeutics, Inc.
Vyome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Vyome Therapeutics, Inc. develops research-based dermatology pharmaceutical solutions. It also develops drugs for antibiotics-resistant acne and other pathogens through a pipeline of antibiotics that retard resistance development. The company was founded by Rajesh Sudhir Gokhale, Rajeev Mantri, Venkateswarlu Nelabhotla, and Shiladitya Sengupta in August 2010 and is headquartered in Princeton, NJ. | Health Technology |
Opal Biosciences Ltd.
Opal Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Opal Biosciences Ltd. develops antimicrobial and anti-infective products. The company was founded in and is headquartered in South Melbourne, Australia. | Health Technology |
Formulytica Pty Ltd.
Formulytica Pty Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Opal Biosciences Ltd., Formulytica Pty Ltd. is a specialty research organization that provides regulatory solutions, training in formulation and analytical techniques, and troubleshooting formulation and analytical methods. The private company is based in Mulgrave, Australia. The Australian company specializes in contract formulation development services, analytical method development and validation, new product development, and the analytical science of semi-solid formulations. Formulytica was acquired by Opal Biosciences Ltd. on May 05, 2021. | Commercial Services |
